Clinical trials: Parkinson Disease Psychosis, active
Schizophrenia, Autism Spectrum Disorder
Cerebellar Stimulation and Cognitive Control
The purpose of this study is to examine whether cerebellar stimulation can be used to improve cognitive deficits and mood in patients with schizophrenia, autism, bipolar disorder, Parkinson's disease, and major depression.
- Conditions
- Schizophrenia, Autism Spectrum Disorder, Bipolar Disorder, Depression
- Trial name
- NCT03217110
- Testing
- Repetitive Transcranial Magnetic Stimulation (rTMS)
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Krystal Parker, PhD
Alzheimer Disease, Dementia With Lewy Bodies (DLB)
Retrospective Observational Study of Blood-based Biomarkers in the Diagnosis and Monitoring of Patients With a Neurodegenerative Disease or Mental Disorder
This is a retrospective observational study to evaluate the clinical utility of blood-based biomarkers in the diagnosis and management of patients with a neurodegenerative disease (ND) or mental disorder (MD).
- Conditions
- Alzheimer Disease, Dementia With Lewy Bodies (DLB), Frontotemporal Dementia (FTD), Major Depressive Disorder (MDD)
- Trial name
- Synapsing-BK (NCT07314190)
- Where
- Spain
- Volunteers
- 1,799 people, healthy volunteers welcome
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Parkinson Disease Psychosis
Clinical Trial Evaluating the Efficacy and Safety of AGB101 for Treatment of Parkinson's Disease Related Psychosis
This clinical trial will test whether AGB101 (low-dose levetiracetam, 220 mg, extended release tablet) can improve symptoms of psychosis in Parkinson's disease.
- Trial name
- AGB101 PDP (NCT05824728)
- Testing
- AGB101
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Johns Hopkins University
Parkinson Disease Psychosis, Amyotrophic Lateral Sclerosis (ALS)
A Phase 1, SAD and MAD Study to Evaluate the Safety and Tolerability of FB418
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics and pharmacodynamics of oral doses of FB418 in healthy adult subjects and healthy elderly subjects.
- Trial name
- NCT05995782
- Testing
- FB418
- Where
- South Korea
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- 1ST Biotherapeutics, Inc.
Clozapine, Parkinson's Disease (PD)
Clozapine-related Immunodeficiency in Parkinsons Disease
Clozapine is a second generation antipsychotic drug used in psychiatry to treat schizophrenia, affective disorders or certain symptoms of dementia.
- Conditions
- Clozapine, Parkinson's Disease (PD), Immunodeficiency, Psychosis
- Trial name
- CLOZIDPD (NCT06634641)
- Testing
- blood test
- Where
- France
- Volunteers
- 24 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Alzheimer Dementia (AD), ALS - Amyotrophic Lateral Sclerosis
Ultra-High Resolution PET in Aging, Neurodegeneration and Psychotic Disorders
The goal of this study is to use ultra-high-resolution (UHR) PET imaging to better understand how the brain and spinal cord change in healthy aging and in neurological and psychiatric disorders such as Alzheimer's disease (AD)…
- Conditions
- Alzheimer Dementia (AD), ALS - Amyotrophic Lateral Sclerosis, Parkinson s Disease, REM Sleep Behavior Disorder (iRBD)
- Trial name
- NCT07509125
- Testing
- UHR PET/CT scan of the brain with ¹⁸F-FDG, UHR PET/CT scan of the brain with ¹⁸F-PE2I, UHR PET/CT scan of the brain with ¹⁸F-SynVesT-1
- Where
- Belgium
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Neurodegenerative Diseases, Parkinson Disease
Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative Diseases
It is hypothesize that patients with clinically diagnosed neurodegenerative diseases will have significantly different receptor occupancy of 5HT2A receptors compared to a healthy age/sex-matched control group.
- Conditions
- Neurodegenerative Diseases, Parkinson Disease, Parkinson Disease Psychosis
- Trial name
- NCT05357612
- Testing
- Pimavanserin
- Where
- United States
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University Medical Center
Alzheimer's Disease Psychosis, Parkinson Disease Psychosis
Effect of Food and Age on the Pharmacokinetics of LY03017
This study consists of 2 parts. Part A is a randomized, open-label, 2-period, crossover study to evaluate the food effect of LY03017 in healthy adults.
- Conditions
- Alzheimer's Disease Psychosis, Parkinson Disease Psychosis, Negative Symptoms of Schizophrenia
- Trial name
- NCT06793995
- Testing
- LY03017
- Where
- China
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Luye Pharma Group Ltd.
Hallucinations and Delusions Associated With Alzheimer's Disease Psychosis, Hallucinations and Delusions Associated With Parkinson Disease Psychosis
A Phase 1, MAD Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LY03017
This is a phase 1，randomized, double-blind, placebo-controlled, MAD study to evaluate the safety, tolerability and pharmacokinetics of oral LPM526000133 Fumarate Capsules (LY03017) in healthy adult subjects
- Conditions
- Hallucinations and Delusions Associated With Alzheimer's Disease Psychosis, Hallucinations and Delusions Associated With Parkinson Disease Psychosis, Negative Symptoms of Schizophrenia
- Trial name
- NCT06980207
- Testing
- LY03017
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Luye Pharma Group Ltd.
Parkinson's Disease Psychosis, Dementia With Lewy Bodies
Comparing Antipsychotic Medications in LBD Over Time
The primary objective of this study is to determine whether treatment with pimavanserin or quetiapine is associated with a greater improvement in psychosis when used in a routine clinical setting to treat hallucinations and/or…
- Trial name
- CAMELOT (NCT05590637)
- Testing
- Pimavanserin, Quetiapine
- Where
- 2 sites in United States
- Volunteers
- 94 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Parkinson's Disease Psychosis
Pimavanserin vs. Quetiapine for Treatment of Parkinson's Psychosis
Patients with Parkinson's disease (PD) sometimes experience symptoms affecting their movement, such as slowness, tremor, stiffness, and balance or walking problems.
- Trial name
- C-SAPP (NCT04373317)
- Testing
- Pimavanserin, Quetiapine
- Where
- 24 sites in United States
- Volunteers
- 358 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development